Renal Cell Carcinoma Therapy Devices Market

Renal cell carcinoma (RCC) is increasing in incidence and one third of newly diagnosed cases already are metastatic. The metastatic spread of solid tumors renders RCC incurable by surgical resection and consequently more difficult to treat. New molecular-targeted therapies have played a pivotal role in RCC treatment.
Renal Cell Carcinoma Therapy Devices Market contains market size and forecasts of Renal Cell Carcinoma Therapy Devices in Global, including the following market information:
Global Renal Cell Carcinoma Therapy Devices Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Renal Cell Carcinoma Therapy Devices market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Directed Energy-based Therapy Devices Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Renal Cell Carcinoma Therapy Devices include AngioDynamics, Inc., Boston Scientific Corporation (Galil Medical, Inc.), IceCure Medical, HealthTronics, Inc., HistoSonics, Inc., Integra LifeSciences Holdings Corporation, Medtronic plc, Monteris Medical, Inc. and Novocure GmbH and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Renal Cell Carcinoma Therapy Devices companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Renal Cell Carcinoma Therapy Devices Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, by Type, 2021 (%)
Directed Energy-based Therapy Devices
Drug/Fluid Delivery and Infusion Therapy Devices
Global Renal Cell Carcinoma Therapy Devices Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Global Renal Cell Carcinoma Therapy Devices Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Renal Cell Carcinoma Therapy Devices Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Renal Cell Carcinoma Therapy Devices revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Renal Cell Carcinoma Therapy Devices revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AngioDynamics, Inc.
Boston Scientific Corporation (Galil Medical, Inc.)
IceCure Medical
HealthTronics, Inc.
HistoSonics, Inc.
Integra LifeSciences Holdings Corporation
Medtronic plc
Monteris Medical, Inc.
Novocure GmbH
Varian Medical Systems, Inc.